Literature DB >> 26325217

Towards programming immune tolerance through geometric manipulation of phosphatidylserine.

Reid A Roberts1,2, Timothy K Eitas1, James D Byrne3,2, Brandon M Johnson1, Patrick J Short4, Karen P McKinnon1, Shannon Reisdorf1, J Christopher Luft3, Joseph M DeSimone3,4,5,6,7, Jenny P Ting1,8,9,10.   

Abstract

The possibility of engineering the immune system in a targeted fashion using biomaterials such as nanoparticles has made considerable headway in recent years. However, little is known as to how modulating the spatial presentation of a ligand augments downstream immune responses. In this report we show that geometric manipulation of phosphatidylserine (PS) through fabrication on rod-shaped PLGA nanoparticles robustly dampens inflammatory responses from innate immune cells while promoting T regulatory cell abundance by impeding effector T cell expansion. This response depends on the geometry of PS presentation as both PS liposomes and 1 micron cylindrical PS-PLGA particles are less potent signal inducers than 80 × 320 nm rod-shaped PS-PLGA particles for an equivalent dose of PS. We show that this immune tolerizing effect can be co-opted for therapeutic benefit in a mouse model of multiple sclerosis and an assay of organ rejection using a mixed lymphocyte reaction with primary human immune cells. These data provide evidence that geometric manipulation of a ligand via biomaterials may enable more efficient and tunable programming of cellular signaling networks for therapeutic benefit in a variety of disease states, including autoimmunity and organ rejection, and thus should be an active area of further research.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Autoimmunity; Immunoengineering; Immunomodulation; Nanoparticles; PLGA; PRINT; Phosphatidylserine; Tolerance; Transplantation

Mesh:

Substances:

Year:  2015        PMID: 26325217      PMCID: PMC4852957          DOI: 10.1016/j.biomaterials.2015.08.040

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  62 in total

1.  Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface.

Authors:  Rinku Majumder; Gabriel Weinreb; Xin Zhai; Barry R Lentz
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

Review 2.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

3.  Phosphatidylserine regulates the maturation of human dendritic cells.

Authors:  Xiao Chen; Kara Doffek; Sonia L Sugg; Joel Shilyansky
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 4.  On regulation of phagosome maturation and antigen presentation.

Authors:  J Magarian Blander; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2006-10       Impact factor: 25.606

5.  Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Authors:  C P Genain; B Cannella; S L Hauser; C S Raine
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

6.  Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials.

Authors:  Jason P Rolland; Benjamin W Maynor; Larken E Euliss; Ansley E Exner; Ginger M Denison; Joseph M DeSimone
Journal:  J Am Chem Soc       Date:  2005-07-20       Impact factor: 15.419

Review 7.  Building different mouse models for human MS.

Authors:  Estelle Bettelli
Journal:  Ann N Y Acad Sci       Date:  2007-03-21       Impact factor: 5.691

Review 8.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

Review 9.  Multiple sclerosis: a complicated picture of autoimmunity.

Authors:  Henry F McFarland; Roland Martin
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

10.  Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo.

Authors:  G C Ramos; D Fernandes; C T Charão; D G Souza; M M Teixeira; J Assreuy
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

View more
  18 in total

Review 1.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

2.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

Review 3.  Mimicking biological functionality with polymers for biomedical applications.

Authors:  Jordan J Green; Jennifer H Elisseeff
Journal:  Nature       Date:  2016-12-14       Impact factor: 49.962

4.  Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.

Authors:  Liliana R Pires; Fernanda Marques; João Carlos Sousa; João Cerqueira; Inês Mendes Pinto
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 5.  Promises of Nanotherapeutics in Obesity.

Authors:  Garrett I Ash; Dongin Kim; Mahua Choudhury
Journal:  Trends Endocrinol Metab       Date:  2019-05-21       Impact factor: 12.015

Review 6.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

7.  Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.

Authors:  Chintan H Kapadia; Shaomin Tian; Jillian L Perry; J Christopher Luft; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2016-09-22       Impact factor: 4.939

Review 8.  In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.

Authors:  Ryan M Pearson; Liam M Casey; Kevin R Hughes; Stephen D Miller; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2017-04-14       Impact factor: 15.470

Review 9.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

10.  Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.

Authors:  Anil Dangi; Xunrong Luo
Journal:  Curr Transplant Rep       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.